Redeye updates its view on Embracer post its Q3 report, which showed solid net sales but weaker profitability. However, Embracer reiterated its guidance for FY 2022/2023e-2023/2024e.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/